Background
Acetylation of DNA-bound core histones constitutes an essential mechanism of epigenetic transcriptional regulation [
1,
2]. Histone acetylation is regulated by two opposing classes of enzymes: histone acetyltransferases (HATs), which transfer the acetyl moiety from acetyl coenzyme A to specific lysine residues of histones and histone deacetylases (HDACs), which catalyze their removal in order to re-establish the positive charge in the histones [
2,
3]. To date, a total of 19 HDACs have been identified in humans, being grouped into three distinct classes, with corresponding homology to the yeast S. Cerevisiae. Among them, class I HDACs is represented by HDAC-1, −2, −3, and −8, with homology to the yeast Rpd3, where the catalytic domain constitutes the majority of the protein, and class II HDACs comprises of HDAC-4, −5, −6, −7, −9, and 10 [
1‐
3].
Both HATs and HDACs have been considered as crucial regulators of cell proliferation, differentiation and apoptosis in various hematological and solid malignancies [
4,
5]. Aberrant deacetylation of histones by enhanced HDAC activity in human tumors has been shown to lead to conformational changes within nucleosome, which results in transcriptional repression of genes involved in differentiation and negative regulation of cell proliferation, migration and metastasis [
6,
7]. Importantly, several HDAC inhibitors (HDACIs) have been shown to induce cell cycle growth arrest in both normal and transformed cells and activate the extrinsic and intrinsic pathways of apoptosis [
6,
7]. Both
in vitro and
in vivo data and ongoing clinical trials have recently revealed that HDACIs could be used against different solid tumors and hematological malignancies, consisting one of the most promising classes of new anticancer agents [
8‐
13].
Pancreatic cancer is one of the most lethal malignant tumors presenting extremely poor prognosis [
14,
15]. Tumor resection is performed in 9–36 % of patients and the 5-year survival rate of patients who have undergone resection is only 19–24 % [
14,
15]. Hence, there is a strong demand for novel specific markers to be explored in respect to pancreatic adenocarcinoma patients’ management and prognosis. Moreover, chemotherapy, such as treatment with 5-fluorouracil or gemcitabine, is not potentially capable of contributing to significant survival benefit according to the available literature data, although their combination is associated with a small survival advantage of about 4 to 8 weeks [
16]. In this aspect, the establishment of alternative therapeutic approaches for the treatment of pancreatic cancer remains a great challenge.
In the last few years, HDACs have been shown to be overexpressed in many human malignancies, including mobile tongue, thyroid, lung, gastric, colorectal, breast, ovarian, endometrial, pancreatic, prostate, brain and renal cell carcinomas as also in hematological malignancies [
17‐
31]. Notably, most of the above studies suggested that HDACs expression was directly associated with tumor dedifferentiation, enhanced proliferation and invasion, disease stage and patients’ prognosis [
17‐
31]. However, the available data so far, evaluating the immunohistochemical expression of HDACs in pancreatic adenocarcinoma remain scarce, being only restricted to HDAC-1 member [
24]. In view of the above considerations, the present study aimed to assess immunohistochemically the expression of HDAC-1, −2, −4 and −6 in tumoral specimens obtained from pancreatic adenocarcinoma patients. We also aimed to evaluate the association of HDAC-1, −2, −4 and −6 expression with clinicopathological characteristics, tumor proliferative capacity and patients’ survival.
Discussion
In the last few years, HDACs have been considered as crucial regulators of cell proliferation, differentiation and apoptosis in various hematological and solid malignancies [
6‐
13]. HDACs overexpression has been described in several types of human malignancy, being associated with crucial clinicopathological parameters for patients’ management and prognosis [
17‐
31]. However, the assessment of their clinical significance in pancreatic adenocarcinoma remains scarce.
In view of above considerations, the present study assessed for the first time the clinical significance of HDAC-1, −2, −4 and −6 expression in pancreatic adenocarcinoma. We found that approximately half of the examined cases presented high HDAC-1, −2, −4 and −6 expression (40.0 %, 50.0 %, 48.6 % and 44.3 %, respectively). Moreover, all the examined cases showed negative HDAC-1, −2, −4 and −6 immunostaining in non-neoplastic sites of pancreatic tissues. The elevated expression levels of HDAC-1, −2, −4 and −6 in pancreatic adenocarcinoma may reinforce the therapeutic utility of HDAC targeting in pancreatic cancer chemoprevention, taking into consideration the anti-cancer properties of HDACIs in cell proliferation, differentiation and apoptosis [
6‐
13]. In this context, the cdk inhibitor p21 was shown to be of the most commonly induced genes in various pancreatic cancer cell lines by several HDACIs [
6,
8]. Transcriptional induction of p21 was associated with G1 cell cycle arrest and growth inhibition. HDACIs also resulted in cell cycle arrest and growth inhibition by transcriptional activation of other cell cycle regulatory genes such as p16, p27, cyclin E and gelsolin, while inhibition of cyclins A, B1, D1 and D2 were also noted in many cancer cell lines. Another mechanism of action for HDACIs concerns the up-regulation of pro-apoptotic proteins Bax, Bad and Bim, and the down-regulation of the anti-apoptotic ones such as Bcl-2, Bcl-XL and surviving [
6‐
8]. HDACIs also reduced the expression of angiogenetic factors, such as VEGF receptors −1 and −2, and affected the expression of a panel of metastasis promoting genes [
6,
8]. Additionally, HDACIs exhibited antiproliferative effects in cancer animal models. Various pancreatic carcinoma cell lines were grown as xenografts in nude mice and treated with HDACIs [
6‐
8]. For most cell lines used, anti-tumor activity and dose-dependent response were observed, with reduction of cell proliferation and induction of apoptosis. Notably, the reduction of pancreatic tumor weight was achieved with minimal toxicity [
6‐
8].
In the present study, HDAC-1 and −2 subcellular distribution was nuclear, whereas HDAC-4 and −6 distribution was cytoplasmic. In accordance to the above findings, class I HDACs are mostly localized within the nucleus due to the lack of a nuclear export signal, whereas class II HDACs shuttle between nucleus and cytoplasm in response to certain cellular signals [
2,
3]. In this aspect, knockout analysis of different class I and class II HDAC proteins indicated that class I HDACs play a role in cell survival and proliferation, whereas class II HDACs may have tissue-specific roles [
2,
3].
The present study further showed that HDAC-1, −2, −4 and −6 immunohistochemical expression was associated with clinicopathological characteristics, which are considered crucial for patients’ management and prognosis. Notably, elevated HDAC-1 expression was significantly associated with increased tumor proliferative capacity, enhanced HDAC-4 expression with the absence of distant metastases and elevated HDAC-6 expression with earlier histopathological stage. Trends of correlation with lymph node metastases and tumor size were also obtained. Enhanced HDAC-1 and −6 expression was further associated with better overall patients’ survival. In agreement with the present findings, recent studies supported evidence that HDACs expression was directly associated with tumor differentiation, proliferation and invasion, disease stage and patients’ prognosis in several human malignancies [
6,
8,
35]. According to a comprehensive and critical review by Weichert, the majority of the existing studies reported an enhanced expression of class I HDAC isoforms in solid human tumours, both on mRNA and protein level [
35]. In most studies, class I HDAC expression was increased in locally advanced, dedifferentiated and strongly proliferating tumours [
35]. In some but not all tumour entities elevated class I HDAC expression was associated with poor patient survival [
35]. However, an association of elevated class I HDAC expression with improved patients’ prognosis for selected tumour types has also been reported [
35]. In contrast to class I isoforms, expression of class II HDACs has been found reduced in tumours and high expression of these isoforms in some tumour types predicted better patients’ outcome [
35]. In fact and in accordance with the present study, elevated HDAC-1 expression was associated with absence of axillary lymph node involvement, smaller tumor size, well tumor differentiation and better disease-free and overall survival in breast cancer [
28]. Moreover, another study documented that enhanced HDAC-6 expression was associated with smaller tumor size and better patients’ survival in invasive breast cancer [
36].
Concerning pancreatic adenocarcinoma, only one study conducted on 55 cases has currently evaluated the clinical significance of HDAC-1 member [
24]. In this study, enhanced HDAC-1 expression was significantly associated with tumor high histological grade and increased proliferative capacity, as also with advanced TNM stage and shorter patients’ survival [
24]. Although inverse correlations were reported by Wang et al. [
25] and us, both studies support evidence for the clinical utility of HDAC-1 expression in pancreatic adenocarcinoma. The discrepancies in the results between the studies could be ascribed to the lower number of pancreatic adenocarcinoma cases (
N = 55) used in the above study compared to our present work (
N = 70), as also to the different primary antibody used to detect HDAC-1 immunoreactivity and the different demographics. Moreover, in the above study the evaluation criteria to semi-quantify HDAC-1 expression was based on the percentage of positively stained tumor cells, whereas in our work they were based on both the percentage of positively stained tumor cells and the staining intensity.
Recently, HDACIs have been introduced into clinical trials, especially in pre-treated and multiply relapsed patients at an advanced cancer stage [
5‐
11]. The first HDACIs tested in clinical trials have shown encouraging anti-tumor effects, at dosages well-tolerated by patients. Importantly, vorinostat was the first HDACI to be approved for clinical use in treating patients with hematological malignancy (cutaneous T-cell lymphoma) [
37]. HDACIs alone and in combination with a variety of cytotoxic or other targeted anticancer agents are currently being tested. Currently, at least ten different HDACIs are under phase II or III clinical studies for the treatment of hematological and solid tumors [
5‐
11]. However, clinical data for HDACIs on patients with pancreatic cancer remains inadequate and only a few studies have included patients suffering from this type of neoplasm [
6,
8]. Additionally, the number of pancreatic cancer patients that entered HDACIs phase II/III trials, among others with advanced solid tumors, is very limited. Although HDACIs are recognized as one of the most promising agents, more studies recruiting for candidates suffering from pancreatic cancer remain to determine the efficiency of these therapies [
6,
8].
Competing interests
All authors verify that they have not accepted any funding or support from an organization that may in any way gain or lose financially from the results of the present study. All authors verify that they have not been employed by an organization that may in any way gain or lose financially from the results of the present study. None authors have any other conflicting interest.
Authors’ contributions
CG: participated in the design and coordination of the study, drafted the manuscript, performed the statistical analysis and contributed to the interpretation of the data, CD: carried out immunoassays and contributed to the interpretation of the data, IK: helped to draft the manuscript, AZ-S: collected and organized the clinical sample, NT: carried out immunoassays and collected clinical sample, EP: contributed to the interpretation of the data, GK: contributed to the interpretation of the data, ST: participated in the design and coordination of the study, drafted the manuscript, has given final approval of the version to be published. All authors read and approved the final manuscript.